MedTrace Logo

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

NCT00339144 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-12-15

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.

Conditions

Interventions

DRUG

Dasatinib

tablets, Oral, 100 mg, once daily for 4 weeks

DRUG

Dasatinib

tablets, Oral, 150 mg, once daily, 4 weeks

DRUG

Dasatinib

tablets, Oral, 200 mg, once daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00339144 on ClinicalTrials.gov